Clinical Trial Update: CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This entry reports a phase 1/2 clinical trial of a CD22-targeted CAR-T therapy for recurrent or refractory B-cell malignancies; the status is not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia

Drugs mentioned

• CD22-targeted CAR-T therapy (CD22-targeted chimeric antigen receptor T-cell)

Snippet

Sponsor: Kai Lin Xu; Jun Nian Zheng | Conditions: Recurrent or Refractory B Cell Malignancy | Phase 1, Phase 2 | Status: UNKNOWN